What are Schizophrenia and Bipolar Disorder?
Schizophrenia is a life-long serious psychiatric illness that causes people to lose touch with reality and often interferes with their ability to think clearly, manage emotions, make decisions and relate to others.
Bipolar disorder, or manic depression, is another life-long psychiatric illness that causes extreme shifts in mood, energy and functioning. These changes may be subtle or dramatic and typically vary greatly over the course of a person’s life as well as among individuals.
- 24 million people worldwide
- Typically manifests between 15 to 35 years of age
- As of 2002, the estimated direct healthcare costs of schizophrenia in the U.S. were $22.7 billion, including patient care, medications and long-term care.
Biopolar Disorder Afflicts:
- 19.6 million people worldwide
- Typically manifests between 15 to 25 years of age
What is NP202?
NP202 is a long-acting formulation of risperidone, an FDA-approved atypical antipsychotic, based on our LAD technology. We are developing NP202 to provide up to three months of continual medication with a single dose in an easy to administer and tolerable dose formulation. This product is designed to address the serious and long-standing problem of non-compliance with medication for patients with schizophrenia or bipolar disorder. We are seeking a development partner for this product candidate.
Addressing Limitations of Current Treatments
Challenge: Medication adherence.
The Clinical Antipsychotic Trials in Intervention Effectiveness, or CATIE, study, conducted between 2001 and 2004, indicated that 74% of schizophrenia patients become non-compliant with their medication within 18 months of commencing the use of medication. Schizophrenia patients with poor compliance are more than twice as likely to experience relapse than patients with good compliance.
Potential Benefit of NP202: Improving patient compliance.
By providing up to three months of continuous medication delivery, we believe NP202 will address issues of medication adherence for schizophrenia and bipolar disorder patients. We believe the continuous treatment provided by NP202 will improve patient compliance, reduce psychotic breaks, reduce physician visits and improve patient functionality.
Challenge: Inability to stop therapy.
With currently available injectable products, physicians and patients cannot stop therapy, which may discourage some physicians and patients concerned about adverse events.
Potential Benefit of NP202: Removable implant.
We are designing NP202 to allow a physician to remove the implant at any time during the dosing period.
Challenge: Medication delivery length.
Currently available extended delivery products provide therapy for only two to four weeks.
Potential Benefit of NP202: Up to three months of medication delivery.
We are developing NP202 to provide up to three months of continuous delivery of an atypical antipsychotic with a single dose. This product will extend delivery well beyond the currently available two- to four-week treatments. We believe this will be a breakthrough for patients with schizophrenia or bipolar disorder.
Challenge: Preparation and mixing.
The leading depot injectable product must be prepared and mixed prior to administration.
Potential Benefit of NP202: Ease-of-administration.
We are developing NP202 as an easy to administer, pre-loaded injectable product that can be stored at room temperature.
Did you know?
- 24 million people suffer from schizophrenia and 19.6 million suffer from bipolar disorder
- Typical onset of symptoms is between 15 to 35 years old
- Annual direct healthcare costs of schizophrenia equals the GDP of Bahrain